Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer

Published:2013-05-01 Issue:5 Volume:18 Page:558-567
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Merseburger Axel S.¹,Bellmunt Joaquim²,Jenkins Cheryl³,Parker Chris⁴,Fitzpatrick John M.⁵,

Affiliation:

1. Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany;

2. Medical Oncology Service, University Hospital del Mar-Institut de Investigacío Médica, Barcelona, Spain;

3. Rocket Science Medical Communications, Wantage, Oxfordshire, United Kingdom;

4. The Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom;

5. Department of Surgery, Mater Misericordiae Hospital University College and Irish Cancer Society, Dublin, Ireland

Abstract

Abstract The arrival of several new agents—cabazitaxel, abiraterone acetate, enzalutamide, and radium-223—is changing the treatment options and management of patients with metastatic castration-resistant prostate cancer (mCRPC). Many other novel agents are also being investigated. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. This review article is a summary of a European Treatment Practices Meeting, which was convened to discuss these latest data on novel agents and current treatment strategies in the mCRPC setting.

Funder

Janssen Pharmaceutical Companies of Johnson & Johnson in Europe

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2012-0478

Reference115 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Global patterns of cancer incidence and mortality rates and trends;Jemal;Cancer Epidemiol Biomarkers Prev,2010

3. Estimates of cancer incidence and mortality in Europe in 2008;Ferlay;Eur J Cancer,2010

4. European cancer mortality predictions for the year 2013;Malvezzi;Ann Oncol,2013

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of interventions for metastatic castration resistant prostate cancer (mCRPC) patients progressing on androgen receptor-axis-targeted (ARAT) therapy: a systematic literature review;Current Medical Research and Opinion;2024-08-27

2. High Mobility Group AT-hook 2: A Biomarker Associated with Resistance to Enzalutamide in Prostate Cancer Cells;Cancers;2024-07-24

3. Causal inferences and real-world evidence: A comparative effectiveness evaluation of abiraterone acetate against enzalutamide;PLOS ONE;2023-10-26

4. MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer;British Journal of Cancer;2021-11-26

5. Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases;Bone Research;2021-05-14